Biosynex supported by CARB-X in the fight against typhoid fever

On February 6, 2026, BIOSYNEX announced that its subsidiary, Chembio Diagnostic Systems Inc., received a $1.8 million grant from CARB-X. This funding is earmarked for the development of a rapid diagnostic test for typhoid fever. This test detects IgA antibodies to identify acute infections caused by Salmonella enterica serovar Typhi. This project is part of an effort to improve diagnostics in low-resource settings, where the disease is a major public health concern.

The rapid serological test will utilize Chembio's DPP® platform. It works with a capillary blood, serum, or plasma sample and delivers results in minutes using the DPP® Micro Reader. This innovation aims to accelerate diagnosis and reduce the inappropriate use of antibiotics. Larry Abensur, president of Biosynex, emphasizes the importance of this initiative in strengthening the rapid detection of high-impact infectious diseases.